Zanamivir: Difference between revisions
No edit summary |
|||
| Line 23: | Line 23: | ||
'''| [[Zanamivir clinical studies|Clinical Studies]]''' | '''| [[Zanamivir clinical studies|Clinical Studies]]''' | ||
'''| [[Zanamivir dosage and administration|Dosage and Administration]]''' | '''| [[Zanamivir dosage and administration|Dosage and Administration]]''' | ||
'''| [[Zanamivir directions for use|Directions For Use]]''' | '''| [[Zanamivir directions for use|Directions For Use]]''' | ||
'''| [[Zanamivir how supplied|How Supplied]]''' | '''| [[Zanamivir how supplied|How Supplied]]''' | ||
Revision as of 21:06, 29 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Zanamivir (INN) (IPA: Template:IPA) is a neuraminidase inhibitor used in the treatment of and prophylaxis of both Influenzavirus A and Influenzavirus B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza. Relenza is the only type of Zanamivir.
Category
Antiviral
US Brand Names
RELENZA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Directions For Use | How Supplied | Labels and Packages
Mechanism of Action
Zanamivir is an inhibitor of influenza virus neuraminidase affecting release of viral particles.